Free Trial

Fox Run Management L.L.C. Makes New Investment in Pfizer Inc. (NYSE:PFE)

Pfizer logo with Medical background

Key Points

  • Fox Run Management L.L.C. has acquired a new position in Pfizer Inc., purchasing 118,511 shares valued at approximately $3 million, making it the fund's 8th largest position.
  • Pfizer's recent quarterly earnings topped expectations, reporting $0.78 EPS against a consensus estimate of $0.58, with revenue of $14.65 billion, which is a 10.3% increase from the previous year.
  • The company declared a quarterly dividend of $0.43 per share, with a yield of 6.8%, indicating a strong commitment to returning value to shareholders despite a high payout ratio of 91.49%.
  • Looking to export and analyze Pfizer data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Fox Run Management L.L.C. bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 118,511 shares of the biopharmaceutical company's stock, valued at approximately $3,003,000. Pfizer comprises about 0.5% of Fox Run Management L.L.C.'s portfolio, making the stock its 8th largest position.

A number of other institutional investors also recently modified their holdings of the stock. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $25.14 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company's fifty day simple moving average is $24.52 and its 200-day simple moving average is $24.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a market cap of $142.93 billion, a PE ratio of 13.37, a P/E/G ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm posted $0.60 earnings per share. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. BMO Capital Markets decreased their price objective on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.12.

Read Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines